AOD-9604: The Growth Hormone Fragment for Fat Metabolism Research
What Is AOD-9604?
AOD-9604, which stands for “Anti-Obesity Drug-9604,” is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). Specifically, it consists of amino acids 176-191 of the full growth hormone molecule, with an additional tyrosine residue substituted at the N-terminus for improved stability.
Originally developed by Metabolic Pharmaceuticals Ltd. in Australia during the 1990s, AOD-9604 was engineered to isolate the fat-metabolizing properties of growth hormone while avoiding its broader metabolic and growth-promoting effects. The peptide represents a targeted approach to harnessing hGH’s lipolytic (fat-burning) activity without triggering the side effects associated with full growth hormone therapy.
AOD-9604 Quick Facts
| Property | Detail |
|---|---|
| Full Name | Anti-Obesity Drug-9604 |
| Structure | 16-amino acid peptide (hGH fragment 176-191 + N-terminal tyrosine) |
| Molecular Formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Developer | Metabolic Pharmaceuticals Ltd. (Australia) |
| Primary Mechanism | Stimulates lipolysis, inhibits lipogenesis |
| IGF-1 Effect | Does not increase IGF-1 levels |
| Glucose Effect | Does not affect blood glucose or insulin sensitivity |
| Clinical Trials | 6 trials, 900+ participants |
| Regulatory Status | Not approved by FDA, EMA, or TGA |
How AOD-9604 Works: Mechanism of Action
The Beta-3 Adrenergic Receptor Pathway
AOD-9604’s primary mechanism involves interaction with beta-3 adrenergic receptors (β3-AR) – the major lipolytic receptors found in fat cells. Research has demonstrated that its effects on fat metabolism are dependent on this receptor pathway.
The Signaling Cascade:
- Receptor Binding – AOD-9604 interacts with β3-AR on adipocytes (fat cells)
- Adenylyl Cyclase Activation – Receptor activation stimulates adenylyl cyclase enzyme
- cAMP Production – Increased intracellular cyclic AMP (cAMP) levels
- PKA Activation – cAMP activates protein kinase A (PKA)
- HSL Phosphorylation – PKA phosphorylates hormone-sensitive lipase (HSL)
- Lipolysis – Activated HSL breaks down stored triglycerides into free fatty acids and glycerol
β3-AR Upregulation
A key finding from animal research is that AOD-9604 increases the expression of β3-AR RNA in fat cells. Importantly, both hGH and the peptide fragment were shown to increase the repressed levels of β3-AR RNA in obese mice to levels comparable with those in lean mice.
The importance of β3-AR was confirmed when researchers tested AOD-9604 in β3-AR knockout mice (animals genetically lacking the receptor). In these mice, chronic treatment failed to produce the changes in body weight and lipolysis observed in normal mice – demonstrating that the receptor is essential for the peptide’s long-term fat-metabolizing effects.
Dual Action: Lipolysis and Anti-Lipogenesis
AOD-9604 works through a dual mechanism:
| Action | Effect |
|---|---|
| Stimulates Lipolysis | Breaks down stored triglycerides into free fatty acids and glycerol for energy |
| Inhibits Lipogenesis | Reduces the formation of new fat from non-fat substrates |
This dual action creates a favorable metabolic environment: increased breakdown of existing fat stores combined with reduced formation of new fat deposits.
What Makes AOD-9604 Unique: Selective Fat Metabolism
Unlike full-length growth hormone, AOD-9604 does not:
- Increase IGF-1 levels – Avoids growth-promoting effects
- Affect glucose metabolism – No hyperglycemia or insulin resistance
- Bind to the GH receptor – Does not activate somatogenic signaling
- Promote cellular proliferation – No growth-related effects
- Cause diabetogenic effects – Neutral impact on glucose homeostasis
This selectivity is what made the compound attractive as a potential anti-obesity drug – it appeared to offer the fat-burning benefits of growth hormone without the associated risks.
AOD-9604 vs. HGH Fragment 176-191: Understanding the Difference
Researchers often encounter both AOD-9604 and HGH Fragment 176-191 in the literature. While they share the same core amino acid sequence, there is a critical distinction:
| Feature | AOD-9604 | HGH Fragment 176-191 |
|---|---|---|
| Core Sequence | hGH amino acids 176-191 | hGH amino acids 176-191 |
| N-Terminal Modification | Tyrosine added | Native phenylalanine |
| Stability | Enhanced | Standard |
| Potency | Higher per unit dose | Lower per unit dose |
| Research Database | Extensive (clinical trials) | Limited |
The tyrosine substitution at the N-terminus improves AOD-9604’s resistance to degradation and extends its functional half-life, making it more suitable for controlled research applications.
What the Research Shows
Preclinical Animal Studies
Obese Mouse Studies
Research in obese mice (both genetically obese Zucker rats and ob/ob mice) demonstrated that AOD-9604:
- Reduced body weight following chronic administration
- Increased lipolytic sensitivity in adipose tissue
- Elevated β3-AR RNA expression to levels comparable with lean mice
- Increased fat oxidation and plasma glycerol levels
- Did not cause hyperglycemia or reduce insulin secretion
A key study found that after 14 days of chronic IP administration, both hGH and AOD-9604 reduced body weight and body fat in obese mice, with results correlating to increased β3-AR expression.
β3-AR Knockout Studies
When tested in mice lacking β3-AR:
- Chronic treatment produced no change in body weight or lipolysis
- However, acute experiments showed AOD-9604 could still increase energy expenditure and fat oxidation through alternative pathways
This confirmed that while β3-AR is essential for long-term effects, AOD-9604 may have additional mechanisms of action for acute metabolic effects.
Human Clinical Trials
AOD-9604 underwent six randomized, double-blind, placebo-controlled clinical trials involving over 900 participants. Here’s what the research showed:
Phase IIa Trial (12 weeks, 300 participants)
| Group | Weight Loss |
|---|---|
| AOD-9604 (1 mg/day) | 2.6 kg average |
| Placebo | 0.8 kg average |
This 12-week trial showed statistically significant weight loss in the AOD-9604 group compared to placebo, representing approximately 1.8 kg greater weight loss.
Phase IIb Trial (24 weeks, 536 participants)
The larger, longer Phase IIb trial failed to demonstrate statistically significant weight loss compared to placebo. This was the critical trial that led to termination of AOD-9604’s development as an anti-obesity drug in 2007.
Safety Profile
Across all clinical trials, AOD-9604 demonstrated an excellent safety profile:
| Safety Parameter | Finding |
|---|---|
| Serious Adverse Events | None reported at therapeutic doses |
| IGF-1 Levels | No increase |
| Blood Glucose | No effect |
| Insulin Sensitivity | No impairment |
| Cortisol Levels | No effect |
| Tolerability | Well-tolerated |
The peptide did not cause the diabetogenic effects, hyperglycemia, or insulin resistance associated with full-length growth hormone therapy.
Why Clinical Development Was Terminated
Despite promising preclinical results and early human trial signals, AOD-9604 development was discontinued in 2007 for one key reason: the magnitude of weight loss was not clinically meaningful in the largest trials.
The peptide didn’t fail because of safety concerns – it failed because it didn’t produce sufficient efficacy to justify approval as an obesity treatment. This highlights an important lesson in drug development: promising mechanisms don’t always translate to meaningful clinical outcomes.
Emerging Research: Cartilage and Joint Health
While its anti-obesity development was terminated, a new and unexpected research application has emerged: cartilage repair and joint health.
Osteoarthritis Research
A 2015 study examined intra-articular AOD-9604 injections in a rabbit model of knee osteoarthritis:
Study Design:
- 32 rabbits with collagenase-induced knee osteoarthritis
- Four treatment groups:
- Group 1: Saline (control)
- Group 2: Hyaluronic acid (HA) alone
- Group 3: AOD-9604 alone
- Group 4: AOD-9604 + HA combination
Results:
| Outcome | Finding |
|---|---|
| Cartilage Degeneration | Significantly lower in all treatment groups vs. saline |
| Best Results | AOD-9604 + HA combination (Group 4) |
| Lameness Recovery | 11±4 days (AOD-9604 + HA) vs. 25±2 days (control) |
| Morphological Scores | Significantly better with AOD-9604 + HA |
The study concluded that “intra-articular AOD9604 injections using ultrasound guidance enhanced cartilage regeneration, and combined AOD9604 and HA injections were more effective than HA or AOD9604 injections alone.”
Proposed Cartilage Mechanisms
In vitro studies suggest AOD-9604 may support cartilage health through:
- Proteoglycan production – Enhanced synthesis in isolated chondrocytes
- Collagen production – Promoted collagen synthesis in cartilage cells
- Mesenchymal stem cell differentiation – Enhanced differentiation into bone
- Myoblast differentiation – Promoted muscle cell differentiation
- Anti-inflammatory effects – Reduced pro-inflammatory cytokines (TNF-α, IL-6, MMPs)
These effects are consistent with the requirements for bone, cartilage, and muscle repair – making AOD-9604 an interesting candidate for osteoarthritis research beyond its original obesity indication.
AOD-9604 vs. Full Growth Hormone
| Factor | AOD-9604 | Full Growth Hormone |
|---|---|---|
| Structure | 16-amino acid fragment | 191-amino acid protein |
| Lipolysis | Stimulates | Stimulates |
| IGF-1 | No increase | Significantly increases |
| Glucose | No effect | May impair glucose tolerance |
| Insulin | No effect | May cause insulin resistance |
| Growth Effects | None | Promotes tissue growth |
| Diabetogenic | No | Yes |
| Cost | Lower | Higher |
| Side Effects | Minimal | Numerous |
The fragment was specifically designed to capture the fat-metabolism benefits of growth hormone while avoiding its broader systemic effects. For more on growth hormone-releasing peptides, see our guides on CJC-1295 and Ipamorelin. This selective profile is both its advantage (fewer side effects) and potentially its limitation (may lack sufficient potency).
AOD-9604 vs. GLP-1 Receptor Agonists
With the rise of GLP-1 medications (semaglutide, tirzepatide) and other fat-targeting peptides like Tesamorelin, many wonder how AOD-9604 compares:
| Factor | AOD-9604 | GLP-1 Agonists |
|---|---|---|
| Mechanism | β3-AR → Lipolysis | GLP-1R → Appetite suppression |
| Primary Effect | Fat metabolism | Appetite/satiety control |
| Weight Loss Magnitude | ~2.6 kg (12 weeks) | 15-20%+ body weight |
| Appetite Suppression | Minimal | Strong |
| FDA Approval | No | Yes (for obesity) |
| Clinical Evidence | Limited | Extensive |
The comparison makes it clear why AOD-9604 never reached market: GLP-1 agonists produce dramatically greater weight loss and have robust clinical evidence supporting their efficacy.
Regulatory Status and Legal Considerations
Current Regulatory Position
| Jurisdiction | Status |
|---|---|
| United States (FDA) | Not approved; removed from Category 2 bulk drug list in 2024 |
| European Union (EMA) | Not approved |
| Australia (TGA) | Not approved (despite Australian development) |
| WADA | Prohibited substance (banned in competitive sports) |
FDA 2024 Decision
In December 2024, the FDA determined that AOD-9604 (both free base and acetate forms) should not be included on the 503A Bulks List for pharmaceutical compounding. The FDA cited:
- Limited long-term safety data
- Peptide impurity concerns
- Potential immunogenicity issues
This decision further restricts the availability of AOD-9604 through compounding pharmacies in the United States.
GRAS Status
Interestingly, AOD-9604 has received GRAS (Generally Recognized as Safe) status for use in food applications – but this is separate from therapeutic drug approval. GRAS status does not mean the compound is approved as a medication.
Safety Considerations
Generally Reported as Well-Tolerated
Based on clinical trial data, AOD-9604 appears to have a favorable safety profile:
Minimal or No Effect On:
- Blood glucose levels
- Insulin sensitivity
- IGF-1 production
- Cortisol levels
- Heart disease risk markers
Potential Side Effects (Generally Mild):
- Injection site reactions (redness, swelling)
- Headache
- Transient fatigue
- Flushing
Important Limitations
While the safety database from clinical trials is reassuring, important limitations exist:
- Long-term data is lacking – Trials were relatively short (up to 24 weeks)
- Large-scale post-market surveillance – Never conducted (drug wasn’t approved)
- Quality concerns – Non-pharmaceutical sources may have purity/sterility issues
- Combination effects – Limited data on interactions with other compounds
Frequently Asked Questions About AOD-9604
What is AOD-9604 used for?
It is a synthetic peptide fragment of growth hormone that was originally developed as an anti-obesity drug. This compound is studied for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without the side effects of full growth hormone. More recently, it has been investigated for potential cartilage repair applications.
Does AOD-9604 work for weight loss?
In a 12-week clinical trial, subjects taking the peptide lost an average of 2.6 kg compared to 0.8 kg in the placebo group. However, a larger 24-week trial failed to show statistically significant weight loss, which led to termination of its development as an obesity treatment in 2007.
Does AOD-9604 increase IGF-1 levels?
No. Unlike full growth hormone, this peptide does not increase IGF-1 levels. This is one of its key distinguishing features – it targets fat metabolism without triggering the growth-promoting effects associated with IGF-1 elevation.
Does AOD-9604 affect blood sugar or insulin?
No. Clinical trials showed the compound does not affect glucose metabolism or insulin sensitivity. This neutral metabolic profile differentiates it from full growth hormone, which can cause hyperglycemia and insulin resistance.
Is AOD-9604 FDA approved?
No. The compound is not approved by the FDA, EMA, TGA, or any major regulatory authority for therapeutic use. In December 2024, the FDA determined it should not be included on the 503A Bulks List for compounding.
What is the difference between AOD-9604 and HGH Fragment 176-191?
Both contain the same core amino acid sequence from growth hormone (residues 176-191). AOD-9604 has an additional tyrosine residue at the N-terminus, which improves stability and potency compared to the native fragment.
Can athletes use AOD-9604?
No. This peptide is prohibited by WADA (World Anti-Doping Agency) and is tested for in competition. Athletes subject to anti-doping regulations must not use this compound.
Does AOD-9604 help with joint pain or cartilage repair?
Emerging preclinical research suggests this peptide may have chondroprotective properties. A rabbit study showed that AOD-9604, especially when combined with hyaluronic acid, enhanced cartilage regeneration in an osteoarthritis model. However, this is early-stage research and not validated for human clinical use.
How does AOD-9604 compare to GLP-1 medications for weight loss?
GLP-1 receptor agonists (like semaglutide) produce significantly greater weight loss (15-20%+ body weight) compared to AOD-9604’s modest effects (~2.6 kg in trials). GLP-1s work primarily through appetite suppression, while AOD-9604 targets fat metabolism. GLP-1s are FDA-approved for obesity; AOD-9604 is not.
Is AOD-9604 safe?
Clinical trials involving over 900 participants showed AOD-9604 was well-tolerated with minimal adverse effects. It did not affect IGF-1, glucose, insulin, or cortisol. However, long-term safety data is limited, and the FDA has cited concerns about peptide impurities and immunogenicity.
The Bottom Line
This peptide represents an innovative approach to targeting fat metabolism by isolating the lipolytic region of growth hormone while avoiding its broader endocrine effects. Its dual mechanism – stimulating lipolysis while inhibiting lipogenesis – offered theoretical advantages for obesity treatment. Clinical trials demonstrated an excellent safety profile, with no effects on IGF-1, glucose metabolism, or insulin sensitivity. However, the peptide failed to produce clinically meaningful weight loss in its largest trials, leading to development termination in 2007. While it remains unavailable as an approved therapeutic, emerging research into its potential cartilage repair properties has opened new avenues for investigation. For researchers studying fat metabolism (see also our article on Injectable L-Carnitine), β3-adrenergic receptor signaling, or growth hormone fragment biology, AOD-9604 remains a valuable tool – but expectations for clinical efficacy must be tempered by its history of failed obesity trials.
Disclaimer: This article is for educational purposes only. NexGen Peptides products are intended for laboratory research use only. Not for human consumption.
References:
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-434.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab.
- Misra M. Obesity pharmacotherapy: Current perspectives and future directions. J Am Diet Assoc. 2013.